Braveheart Bio (BRVE) Stock Insights

BRVE price $21.76 -0.06 -0.27%

Ticker
BRVE
Price
$21.76
Change
-0.06 -0.27%
Market cap ?
$1.54B
Sector
Healthcare
Industry
Biotechnology

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Fair value

BRVE fair value Not meaningful. Price $21.76.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare BRVE

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-12-08—-0.91——
2026-09-08-2.512.69——

Dividends

Yield —. Payout ratio —. Frequency —.

Safety score 34/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. Yield is unknown, so this part stays neutral.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-08-07Agarwala VineetaOther0——
2026-08-07AH Bio Fund IV, L.P.Buy1.10M$18.0019.80M
2026-08-07AH Bio Fund IV, L.P.Buy9.13M——
2026-08-07AH Bio Fund IV, L.P.Sell40.00M——
2026-08-07Chimovits ErezBuy1.67M$18.0030.00M
2026-08-07Chimovits ErezBuy9.13M——
2026-08-07Chimovits ErezBuy273.33K$18.004.92M
2026-08-07Chimovits ErezSell40.00M——
2026-08-07ORBIMED ADVISORS LLCBuy1.67M$18.0030.00M
2026-08-07ORBIMED ADVISORS LLCBuy9.13M——
2026-08-07ORBIMED ADVISORS LLCBuy273.33K$18.004.92M
2026-08-07ORBIMED ADVISORS LLCSell40.00M——
2026-08-07Jiangsu Hengrui Pharmaceuticals Co., Ltd.Buy7.42M——
2026-08-07Jiangsu Hengrui Pharmaceuticals Co., Ltd.Sell32.50M——
2026-08-07Forbion Growth Opportunities Fund III Cooperatief U.A.Buy1.92M$18.0034.56M
2026-08-07Forbion Growth Opportunities Fund III Cooperatief U.A.Buy1.68M$18.0030.24M
2026-08-07Forbion Growth Opportunities Fund III Cooperatief U.A.Buy9.13M——
2026-08-07Forbion Growth Opportunities Fund III Cooperatief U.A.Buy7.99M——
2026-08-07Forbion Growth Opportunities Fund III Cooperatief U.A.Sell35.00M——
2026-08-07Rickey James PaulBuy27.78K$18.00499.99K
2026-08-07Viehbacher ChristopherBuy83.33K$18.001.50M
2026-08-07Malek David IBuy4.17K$18.0074.99K
2026-08-07Anderson Michele A.Buy1.11K$18.0020.00K
2026-08-07Murdoch TravisBuy83.33K$18.001.50M
2026-08-07Lubner David CharlesBuy55.55K$18.00999.99K
2026-08-05Rickey James PaulBuy300.00K$18.005.40M
2026-08-05Lohoff TimBuy30.00K$18.00540.00K
2026-08-05Chimovits ErezBuy30.00K$18.00540.00K
2026-08-05Viehbacher ChristopherBuy30.00K$18.00540.00K
2026-08-05Malek David IBuy30.00K$18.00540.00K
2026-08-05Anderson Michele A.Buy300.00K$18.005.40M
2026-08-05Murdoch TravisBuy550.00K$19.8010.89M
2026-08-05Bos JasperBuy30.00K$18.00540.00K
2026-08-05Lubner David CharlesBuy60.00K$18.001.08M
2026-08-05Jiangsu Hengrui Pharmaceuticals Co., Ltd.Other7.42M——
2026-08-05ORBIMED ADVISORS LLCOther0——
2026-08-05ORBIMED ADVISORS LLCOther9.13M——
2026-08-05AH Bio Fund IV, L.P.Other9.13M——
2026-08-05Forbion Growth Opportunities Fund III Cooperatief U.A.Other0——
2026-08-05Forbion Growth Opportunities Fund III Cooperatief U.A.Other0——
2026-08-05Forbion Growth Opportunities Fund III Cooperatief U.A.Other7.99M——
2026-08-05Rickey James PaulOther0——
2026-08-05Rickey James PaulOther0——
2026-08-05Viehbacher ChristopherOther0——
2026-08-05Viehbacher ChristopherOther0——
2026-08-05Bos JasperOther0——
2026-08-05Lubner David CharlesOther0——
2026-08-05Anderson Michele A.Other0——
2026-08-05Anderson Michele A.Other70.78K$3.07217.28K
2026-08-05Chimovits ErezOther0——
2026-08-05Chimovits ErezOther9.13M——
2026-08-05Murdoch TravisOther0——
2026-08-05Murdoch TravisOther0——
2026-08-05Murdoch TravisOther0——
2026-08-05Lohoff TimOther0——
2026-08-05Malek David IOther0——
2026-08-05Malek David IOther0——
2026-08-05Coloma Jason VOther0——
2026-08-05Coloma Jason VOther0——

Institutional holders

HolderSharesChangeChange %Value
No data yet.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Braveheart Bio (BRVE) Stock Insights

BRVE$21.76-0.06 -0.27%

$1.54B

Market Cap

—

P/E

—

Forward P/E

—

Score

Price History